Johnson & Johnson (JNJ)
Summary
JNJ Chart
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.
Johnson & Johnson Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 66,416 | $11.13M | $16.68M | $5.55M | 49.86% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 13,582 | $2.26M | $3.41M | $1.15M | 50.88% |
| MSH Michelle S. Hickox FIRST FINANCIAL BANKSHARES Inc. | 629,377 | $99.36M | $158.18M | $58.82M | 59.2% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 18,845 | $3.2M | $4.73M | $1.54M | 48.03% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 22,946 | $3.4M | $5.76M | $2.36M | 69.29% |
Johnson & Johnson Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Larry Biegelsen Wells Fargo | 400.05 | $100,000 | $100,000 | - | - |
| JB Jayson Bedford Raymond James | 1,132.14 | $283,001.44 | $283,001.44 | - | - |
 Joanne Wuensch Citigroup | 94.91 | $25,000 | $24,185.65 | -$814.35 | -3.26% |
| MN Michael Nedelcovych TD Cowen | 414.42 | $100,000 | $105,120.18 | $5,120.18 | 5.12% |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Media Industry | Communication Services Sector | Joaquin Duato CEO | NYSE Exchange | 478160104 CUSIP |
| US Country | 141,700 Employees | 9 Jun 2026 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
